Use of Multi-Site Radiation Therapy for Systemic Disease Control
- PMID: 32798606
- PMCID: PMC10644952
- DOI: 10.1016/j.ijrobp.2020.08.025
Use of Multi-Site Radiation Therapy for Systemic Disease Control
Abstract
Metastatic cancer is a heterogeneous entity, some of which could benefit from local consolidative radiation therapy (RT). Although randomized evidence is growing in support of using RT for oligometastatic disease, a highly active area of investigation relates to whether RT could benefit patients with polymetastatic disease. This article highlights the preclinical and clinical rationale for using RT for polymetastatic disease, proposes an exploratory framework for selecting patients best suited for these types of treatments, and briefly reviews potential challenges. The goal of this hypothesis-generating review is to address personalized multimodality systemic treatment for patients with metastatic cancer. The rationale for using high-dose RT is primarily for local control and immune activation in either oligometastatic or polymetastatic disease. However, the primary application of low-dose RT is to activate distinct antitumor immune pathways and modulate the tumor stroma in efforts to better facilitate T cell infiltration. We explore clinical cases involving high- and low-dose RT to demonstrate the potential efficacy of such treatment. We then group patients by extent of disease burden to implement high- and/or low-dose RT. Patients with low-volume disease may receive high-dose RT to all sites as part of an oligometastatic paradigm. Subjects with high-volume disease (for whom standard of care remains palliative RT only) could be treated with a combination of high-dose RT to a few sites for immune activation, while receiving low-dose RT to several remaining lesions to enhance systemic responses from high-dose RT and immunotherapy. We further discuss how emerging but speculative concepts such as immune function may be integrated into this approach and examine therapies currently under investigation that may help address immune deficiencies. The review concludes by addressing challenges in using RT for polymetastatic disease, such as concerns about treatment planning workflows, treatment times, dose constraints for multiple-isocenter treatments, and economic considerations.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest:
All other authors declare no relevant conflicts of interest.
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10644952/bin/nihms-1621786-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10644952/bin/nihms-1621786-f0002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10644952/bin/nihms-1621786-f0003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10644952/bin/nihms-1621786-f0004.gif)
![Figure 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10644952/bin/nihms-1621786-f0005.gif)
Similar articles
-
Is Single-Site Radiation Therapy Enough to Augment the Immune System and Enhance Immunotherapy for Metastatic Disease?Semin Radiat Oncol. 2024 Jul;34(3):272-275. doi: 10.1016/j.semradonc.2024.05.003. Semin Radiat Oncol. 2024. PMID: 38880535 Review.
-
Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.J Immunother Cancer. 2021 Jun;9(6):e002715. doi: 10.1136/jitc-2021-002715. J Immunother Cancer. 2021. PMID: 34172518 Free PMC article.
-
The biology of prostate cancer metastases: does oligo differ from polymetastatic?Curr Opin Urol. 2017 Nov;27(6):542-546. doi: 10.1097/MOU.0000000000000434. Curr Opin Urol. 2017. PMID: 28786848 Review.
-
Survival, local control, and health-related quality of life in patients with oligometastatic and polymetastatic spinal tumors: A multicenter, international study.Cancer. 2019 Mar 1;125(5):770-778. doi: 10.1002/cncr.31870. Epub 2018 Nov 29. Cancer. 2019. PMID: 30489634 Free PMC article.
-
Integration of radiotherapy and immunotherapy for treatment of oligometastases.Lancet Oncol. 2019 Aug;20(8):e434-e442. doi: 10.1016/S1470-2045(19)30157-3. Epub 2019 Jul 29. Lancet Oncol. 2019. PMID: 31364595 Review.
Cited by
-
Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.Heliyon. 2024 Feb 27;10(5):e27103. doi: 10.1016/j.heliyon.2024.e27103. eCollection 2024 Mar 15. Heliyon. 2024. PMID: 38449655 Free PMC article.
-
Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.Front Immunol. 2024 Feb 1;15:1321946. doi: 10.3389/fimmu.2024.1321946. eCollection 2024. Front Immunol. 2024. PMID: 38361930 Free PMC article.
-
Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting.Biomolecules. 2023 Apr 18;13(4):689. doi: 10.3390/biom13040689. Biomolecules. 2023. PMID: 37189436 Free PMC article. Review.
-
PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report.Front Oncol. 2023 Apr 28;13:1078915. doi: 10.3389/fonc.2023.1078915. eCollection 2023. Front Oncol. 2023. PMID: 37188188 Free PMC article.
-
Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center.Discov Oncol. 2023 May 4;14(1):55. doi: 10.1007/s12672-023-00666-7. Discov Oncol. 2023. PMID: 37142872 Free PMC article.
References
-
- Loi M, Desideri I, Greto D, et al. Radiotherapy in the age of cancer immunology: Current concepts and future developments. Critical reviews in oncology/hematology. 2017;112:1–10. - PubMed
-
- XXX [BLINDED]
-
- XXX [BLINDED]
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical